Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
They obviously cannot get a partner for an unproven new science...
LOL...no dilution...hahahaha...they can't get a partner and now have to go at it alone.
Anavex doesn't need the money. But it's sending a clear signal that Dr. Missling getting his ducks in a row in case he doesn't receive any legitimate partnership offers. I don't think he wants to go at it alone but having access to cash is never a bad thing, because the cost of manufacturing and marketing will easily eat up all of the runway needed to get the other trials complete and further advance A371.
The market rose as Powell began speaking of an end in sight with the rampant inflation, and the markets faded just as quickly when it became clear the process was going to take a very long time. Overlay the AVXL chart with the DJIA chart and you can see exactly when the spike and drop occurred across the entire market.
The price action had very little to do with Dr. Missling or the company as whole. If anything, one analyst allegedly lowered his price target from $80 to $58.
Dude has been playing with ChatGPT AI.... here is a sample Q&A.....
Question - How should publicly traded companies communicate with shareholders?
Answer - Publicly traded companies should communicate with shareholders in a transparent, timely, and accurate manner. This can be achieved through various channels such as earnings releases, annual reports, investor presentations, conference calls, and other regulatory filings such as SEC filings. Additionally, companies can also use social media, websites, and email to reach shareholders. The goal of these communications should be to provide shareholders with a clear understanding of the company's financial performance, strategy, and prospects, and to respond to questions and concerns in a prompt and helpful manner.
More verbal diarrhea!
Wow, an ATM agreement. (Yawn)
Good question..
If partnership was in works i don’t think they would need agreement w vulture firm…they could just file for more shares
If no p3 needed for ad, then, 4 years of cash should have been enough..so its curious timing
So that leaves one option imo..
Wow. I think the AGM should start with everyone singing Kumbaya.
The communication you describe would be nice. It is not close to essential.
What is essential is the company delivering on developing and marketing a drug.
You don't know how LPC vulture works, Misleading used them earlier, diluted from 25mil to 70mil shares in 5year, collecting pennies. LPC is his comfort zone, he might be expecting share to drop big time and needed continues ATM.
It takes a lot of money to do trials and commercialize drugs for every human disease known to man.
In over 38 years Big Pharmas or, biotech companies that focused exclusively on the plaque/tau none have been successful in their treatment of the disease of AD. Even our FDA in desperation to find a meaningful approach to this catastrophic disease approved 2 Biogen drugs that do little to alleviate the significant issues of the disease ... plus their drugs are very expensive, must be given I.V. and must be done by medical personnel ... adding more expense for the treatment .... and the treatment can cause the patient's brain to bleed, which could result in the patient's death. Summed up, just more failures with this dangerous approach.
Am awaiting the approval of Anavex's blarcamesine drug/2 - 73, a safe drug, a pill taken by mouth, that has demonstrated significant results with neuro-degenerative and neuro-developmental diseases affecting the CNS.
Missling is back in bed with vulture investor LPC but not because he couldn’t get any real WS banks to take it on. It’s because he doesn’t want to have to answer hard questions from sophisticated institutional investors or be accountable to those investors who might buy in.
Another fudster masquerading as a shareholder. How refreshing.
Haha. My takes from CM’s CC.
1. AD full data. In 2023? Not sure — could be 2024, 2025. But, I assure you asap.
2. Excellence trial endpoint. RIGHT NOW, our plan is delta-RSBQ, but you know us — can’t promise what it will be in 2 months, or when we see the data.
3. PDD OLD. Oops, are you guys still waiting for it?! Give us 6-12 more months. We need a few more months to compute an average of 400 values.
4. AD discussion with FDA. After we get our “hands” on full data (see #1 above), then we’ll talk **aggressively** with the agencies. Just 1-2 more years wait.
5. Other trials: All our previous trials have failed — so we are being extra cautious that these new ones succeed. So, that’s the reason for delay.
6. PDD trial full data: Forget about it!
The obsession with this dead-end approach has been fanatical, almost cultlike.
There's a lot of that going around these days....
Steve Forbes Forbes Staff
“With all thy getting, get understanding."
Feb 7, 2023,06:00am EST
Why is there no cure for Alzheimer’s—or why aren’t there medications that can at least substantially slow or meaningfully ameliorate the disease? It afflicts more than 6 million Americans, with that number on its way to doubling within a generation.
Alzheimer’s is a hideous ailment for both the sufferers and their families and friends. Yet even though the disease was first diagnosed by psychiatrist Alois Alzheimer in the early 1900s, progress in fighting it has been almost nonexistent. What’s scandalous is that for decades research has been almost entirely focused on the wrong hypothesis.
Dr. Alzheimer noted in the autopsy of the patient’s brain with the disease that came to bear his name that it was densely loaded with two proteins called plaques and tangles. Unfortunately, the dominant thesis in research on the disease has been that attacking plaques, and to a lesser extent tangles, would cure the ailment and enable the brain to regain its health.
Alzheimer himself warned about focusing too much on plaques and tangles as causes. In fact, some sufferers of Alzheimer’s have proved to have had little in the way of plaques, while others who had plaques didn’t have the disease.
Nonetheless, despite constant failures—some 20 drugs have been developed that ended up as flops—and the expenditure of tens of billions of dollars, the main thrust of research remains focused on fighting plaques.
The obsession with this dead-end approach has been fanatical, almost cultlike. Researchers who want to pursue more promising avenues have faced serious obstacles. Rarely has chronic failure resisted correction on something so important.
You may have heard of a new drug called lecanemab, which is being heralded as a fantastic breakthrough. But lecanemab is based on the wrongheaded plaques hypothesis. As noted health policy journalist Joanne Silberner sadly points out, “At best, lecanemab might slightly slow a patient’s inevitable decline for a few months.”
This research scandal shows the danger of groupthink, particularly when there’s a powerful government agency such as the National Institutes of Health putting the kibosh on grants for nonconsensus projects.
A classic case of similar groupthink involved the cause of stomach ulcers. The once-prevailing view was that stress and lifestyle were the cause, and drugs and regimens were developed on that belief.
This dogma was challenged by two Australian physicians, Robin Warren and Barry Marshall. They posited that the villain was bacteria and that antibiotics were the answer for a permanent cure. When not ignored, their discoveries were derided. Only after many years and constant, sometimes unorthodox advocacy, especially by Dr. Marshall, did the medical world accept their truths. The two were eventually awarded the Nobel Prize in Medicine.
In the case of Alzheimer’s, the rigid research mentality has begun to soften, but only slightly. To attack this deadly rigidity, Congress should hold hearings on the subject, starting with the leaders at the National Institutes of Health.
Steve Forbes is Chairman and Editor-in-Chief of Forbes Media.
https://www.forbes.com/sites/steveforbes/2023/02/07/the-scandal-of-alzheimers/?sh=34284da66a41&bsft_aaid=a4679c91-eb03-4591-93c2-79b7f25f9cbd&bsft_eid=15374f1b-1165-4402-b482-cdabfc723dde&utm_source=blueshift&bsft_clkid=39bb3ca5-f842-4f84-a918-78a3d2514c58&bsft_uid=8a4ab049-cac4-4359-ae99-bc1e70d3b870&bsft_mid=6fae9050-ef21-411e-9d1c-4e5f7b0849ca&bsft_utid=8a4ab049-cac4-4359-ae99-bc1e70d3b870-DRPROOF&bsft_mime_type=html&bsft_ek=2023-02-07T21%3A30%3A36Z&bsft_lx=20&bsft_tv=4&pk=ce01a6586b8394cd219d9d4151b05359&utm_campaign=DAP_ISSUE_02.07.23&utm_medium=email&vid2=9cd562d8abdeeda86039a61cc7e5dc63e585d49a727e626584f7ccd81870dffd80f6507937c7784a56ba72af38c88171
He is expecting another huge run very SOON!
TGD is think only 3M shares.
They will sell shares from time to time at Missling's discretion....not at LPC's
So much for debt financing. Unbelievable!
Posted on ST... posted earlier on IH by xodcode.
https://www.conferencecalltranscripts.org/summary/?id=11773683
Active link for Edgar filings.
Average price estimate from these IBs is ~$50 so you can see how valuable their opinions are.
I guess investors forgot BlackRock,Inc bought 5.5 million shares of Anavex Life Sciences common stock for a reason that they believed it was a very, very, very good investment for their customers. Maybe other investors might now become a bit more savvy? After all BlackRock,Inc. is a fiduciary whose current value in it's stock positions exceeds $8.6 Trillion Dollars ... that figure IS NOT A TYPO ............
This will give Anavex the flexibility to raise cash as needed without selling their soul to an investment Bank. This continues Dr.M's independence from Wall Street. Some people will view it positive some negative. When a capital partner has done well in the past, as LPC has, you keep the relationship going. LPC obviously finds no problem placing the shares.
Cantor Fitzgerald is probably pissy they didn't get the business hence their low price target. Investment bankers are a truly petty egoist bunch.
Kund...LP will pay how much per share under this agreement?? Market price at the time of purchase??
What is the date on that contract for 3-71?
Wow... you nailed it again! There's FUD in every aspect of every situation...
Why the sudden need for money?
Was that really worth the effort? SMH
Always put positive spin...who will partner with a company who is lying about data and end points? Questionable data don't attract any partners, he might have begged few, every one told him to get lost, hence he went back to vulture finance LP.
His cash on hand statement includes ATM....
Especially when we think they are close to commercialization
Why the need for a new ATM agreement with $140 million on hand???!!!
Has AVXL management decided to go it alone? (as opposed to partnering?)
Misleading back in action with LP, he realized life is better with LP..cash on hand never goes down
Missling is throwing in with the dirt bags at Lincoln Park again. Couldn’t get any real WS banks to take it on.
Wait, what? BRIEF-Anavex Life Sciences Corp Files Prospectus Supplement Relates To Issuance, Sale Of Up To $150 Million In Shares Of Common Stock From Time To Time
REUTERS 5:36 PM ET 2/7/2023
Symbol Last Price Change
AVXL 11.75up +0.64 (+5.7606%)
QUOTES AS OF 04:00:00 PM ET 02/07/2023
Feb 7 (Reuters) - Anavex Life Sciences Corp(AVXL):
* ANAVEX LIFE SCIENCES CORP FILES PROSPECTUS SUPPLEMENT RELATES TO ISSUANCE AND SALE OF UP TO $150 MILLION IN SHARES OF COMMON STOCK FROM TIME TO TIME
* ANAVEX FILES PROSPECTUS SUPPLEMENT RELATES TO ISSUANCE, SALE OF UP TO ADDITIONAL 150,000 COMMON SHARES ISSUED AS COMMITMENT SHARES TO LINCOLN PARK Further company coverage:
MARKET rally into the close is the reason to think AVXL rise will hold?
I missed .70....so far, but not convinced NEWS is the reason.
"Perhaps the analysts are losing interest and had better things to do this morning."
TGD's MO is never to say much...With that said why bother to be on the call....Let the results speak for themselves.
Little birdie says 20 by eom. tweet, tweet...time for birdies to eat the mealworms!!
Interesting that only two of the five covering analysts were on today’s call and only asked a couple of questions. Also, the newsletter writer that always asks questions was apparently not on the call. Although the stock is moving up with the market, it’s notable that all but two of the covering analysts were either not on the call or had no questions. (It seems unlikely to me that they’d be on but have no questions.) And of course there were no institutional investors on the call since only index funds own AVXL. Also, has anyone seen an analyst research note based on this morning’s call? I haven’t.
Perhaps the analysts are losing interest and had better things to do this morning.
Twice Worthy
I bonds willadjust, but
Integral part of wife's security.
Followers
|
1065
|
Posters
|
|
Posts (Today)
|
20
|
Posts (Total)
|
459701
|
Created
|
12/18/07
|
Type
|
Free
|
Moderators RedShoulder Steady_T Bourbon_on_my_cornflakes kund mike_dotcom nidan7500 |
Anavex®Life Sciences Corp. (the “Company”) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including drug candidates to treat Alzheimer’s disease, other central nervous system (“CNS”) diseases, pain and various types of cancer. The Company’s lead compound ANAVEX®2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome.
Anavex®Life Sciences’ lead drug candidate, ANAVEX®2-73, recently completed successfully a Phase 2a clinical trial for Alzheimer’s disease. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others. The Michael J. Fox Foundation for Parkinson’s Research has awarded Anavex® a research grant to develop ANAVEX®2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX®2-73 into a Parkinson’s disease clinical trial. ANAVEX®3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions.
The Company is in preparation for ANAVEX®2-73 for a Phase 2/3, placebo-controlled trial in Alzheimer’s disease as well as a Phase 2, placebo-controlled trial in Rett syndrome, for which the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for ANAVEX®2-73 and a Phase 2, placebo-controlled trial in Parkinson’s disease.
Headquartered in New York, Anavex® Life Sciences is an American publicly traded corporation on Nasdaq quoted as AVXL
.Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |